
Annual Highlights of Genuine Biotech in 2025

During the conference, the "2025 Capital Market Most Valuable Influential List" was unveiled. Genuine Biotech won the "Most Investment Potential Award" for its outstanding performance and industry leadership.

Recently, the "Technology Empowers, Capital Breaks Through" sharing meeting sponsored by GuruClub was successfully held, during which the "Jinge Award" - the list of excellent companies of the year was officially unveiled, and Genuine Biotech won the "Excellent Biopharmaceutical Company of the Year" Award by virtue of its outstanding performance and professional strength in the biopharmaceutical field.

Recently, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted approval to Henan Genuine Biotech Co., Ltd. (Genuine Biotech) to initiate a Phase IIa clinical trial of its GEN-725 Tablets (Azvudine), intended for the treatment of hematological malignancies.

On 9 November, according to the disclosure from the Hong Kong Stock Exchange (HKEX), Genuine Biotech Limited (hereinafter referred to as "Genuine Biotech") has submitted its application for listing on the Main Board of HKEX, advancing an important step in the company's development.

The next-generation "small molecule drug" + "novel toxin" dual-platform project independently developed by Genuine Biotech will be presented at the AACR annual meeting as "Late-Breaking Research".

Recently, at the BIOCHINA 2025 10th International Convention, the BIOCHINA Awards 2024 List was announced. Genuine Biotech, with its breakthrough R&D achievements, won the "2024 Innovation Breakthrough Enterprise Award".

On Feb. 2, Wang Zhaoyang, founder of Genuine Biotech, was invited to the new year government-enterprise exchange conference held by the CPC Henan Province Committee and the People's Government of Henan Province.